Buying a Chunk of Jurilab, Nanogen Gets CYP450 Chip, Fodder for New Cardio Dxs | GenomeWeb

With an investment of about $1.5 million, Nanogen has acquired around 20 percent of Finland-based Jurilab, and gained access to a wealth of genotyping data to complement its cardiovascular diagnostic offerings — along with Jurilab's drug-metabolizing enzyme microarray.

Nanogen said it expects its investment in Jurilab to be followed "within six months" by an investment of equal size. The company also retains the right to buy the Finnish firm at a fixed, but undisclosed price, according to Robert Saltmarsh, Nanogen CFO.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.